Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

In patients with primary resectable breast cancer, a positive correlation between the age and the count of CD16+ lymphocytes and a negative correlation of this parameter with the number of regulatory CD4+CD25+CD127 cells and proliferative activity of Ki-67 tumor cells were revealed. Higher level of Ki-67 was associated with reduced number of effector lymphocytes (CD8+ and CD16+) and elevated content of regulatory CD8+CD11bCD28 T cells. The absence of expression of estrogen receptors was associated with reduced cytotoxic potential of CD8+ T cell in comparison with ER+ breast cancer. The percentage of CD8+ lymphocytes (CD3+CD8+ and CD8+CD11b+CD28+) among lymphocytes infiltrating the tumor was higher in PR+ breast cancer than in PR tumors. With increasing the tumor load, the number of lymphocytes expressing CD16 marker and their cytotoxic potential decreased.

Об авторах

T. Zabotina

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Автор, ответственный за переписку.
Email: tatzabotina@yandex.ru
Россия, Moscow

O. Korotkova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

A. Chertkova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

E. Zakharova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

D. Tabakov

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

N. Dzhgamadze

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

M. Savostikova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

E. Artamonova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

V. Khailenko

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

E. Kovalenko

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

Z. Kadagidze

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Россия, Moscow

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Springer Science+Business Media, LLC, part of Springer Nature, 2018

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).